Tonix制药控股 TNXP 深 沪
已收盘 05-15 16:00:00 美东时间
15.74
+1.650
+11.71%
华盛通- 最 高15.8214
- 今 开13.71
- 成交量 72.47万股
- 最 低 13.50
- 昨 收 14.09
- 总市值 2.24亿
- 52周最高 69.97
- 市盈率 静 --
- 换手率 5.10%
- 52周最低 11.6028
- 委 比 -80.04%
- 总股本 1420.54万
- 历史最高 13440000000.00
- 量 比 1.96
- 振 幅 16.48%
- 历史最低 11.6028
- 每 手 1
- 风险率 11.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tonix Pharma advances TNX-4800 Lyme vaccine program
Tonix Pharma ( ($TNXP) ) has issued an announcement. On May 15, 2026, Tonix Pha...
05-15 21:48
Tonix Pharmaceuticals Q1 EPS $(2.93) Misses $(2.43) Estimate, Sales $6.878M Beat $6.100M Estimate
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.93) per share which missed the analyst consensus estimate of $(2.43) by 20.58 percent. This is a 3.17 percent decrease over losses of $(2.84) per share
05-12 04:36
Why Tonix Pharmaceuticals Shares Are Rallying Wednesday
Tonix Pharmaceuticals Holding shares are trading higher Wednesday after announcing commercial payer coverage for fibromyalgia drug TONMYA.
05-06 20:56
Tonix rises on commercial payer coverage for pain therapy
Tonix Pharmaceuticals (TNXP) added ~6% in the premarket on Wednesday after announcing an agreement with a group purchasing organization to secure commercial payer coverage for Tonmya, its non-opioid p...
05-06 20:12
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
TD Cowen Initiates Coverage On Tonix Pharmaceuticals with Buy Rating, Announces Price Target of $22
TD Cowen analyst Stacy Ku initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy rating and announces Price Target of $22.
05-05 01:52
财报速睇 | Tonix制药控股 2026财年Q1营收0.07亿美元，同比增长187.5%；归母净利润亏损0.41亿美元，同比亏损扩大142.9%
华盛资讯5月2日讯，Tonix制药控股公布2026财年Q1业绩，公司Q1营收0.07亿美元，同比增长187.5%，归母净利润亏损0.41亿美元，同比亏损扩大142.9%。
05-02 06:34
Tonix Pharma Announces Administrative Update to Regulatory Filing
Tonix Pharma ( ($TNXP) ) has issued an update. Tonix Pharma disclosed that cert...
05-02 06:12
Tonix Pharma Announces Oral Presentation And Two Poster Presentations On Preclinical Immuno-Oncology Portfolio At AACR Annual Meeting 2026
TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significantly attenuated tumor progression in aged gastric microenvironment in preclinical modelsTNX-1700 exhibited
04-23 19:11
Tonix Pharmaceuticals Announces Publication Of The Paper "Steady-State Pharmacokinetic Properties Of TNX-102 SL, A Sublingual Tablet Formulation Of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing In Healthy Volunteers: A Randomized, Open-label Trial," In The Journal 'Clinical Pharmacology In Drug Development'
The publication reports findings from a single-center, randomized, open-label, multiple-dose, parallel-group pharmacokinetic study conducted in 60 healthy adult volunteers. Participants were randomized 1:1 to receive
04-15 19:07
